Cargando…

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality

Detalles Bibliográficos
Autores principales:	Paneth, Nigel, Casadevall, Arturo, Joyner, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404652/ https://www.ncbi.nlm.nih.gov/pubmed/37554952 http://dx.doi.org/10.1002/hsr2.1463

Ejemplares similares

Use of convalescent plasma in the treatment of COVID-19
por: Joyner, Michael J., et al.
Publicado: (2023)

Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
por: Casadevall, Arturo, et al.
Publicado: (2021)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?
por: Casadevall, Arturo, et al.
Publicado: (2021)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

‘Treatment of COVID-19 with convalescent plasma’ – Author’s reply
por: Wooding, Denise J., et al.
Publicado: (2021)

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?
por: Franchini, Massimo, et al.
Publicado: (2023)

In Reply—How Safe Is COVID-19 Convalescent Plasma?
por: Joyner, Michael J., et al.
Publicado: (2021)

Late Treatment for COVID-19 With Convalescent Plasma
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

In Reply — Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Joyner, Michael. J., et al.
Publicado: (2020)

Use of convalescent plasma in COVID‐19 patients with immunosuppression
por: Senefeld, Jonathon W., et al.
Publicado: (2021)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

HLA Antibody Rates Are Not Increased in a Regional Group of Male COVID-19 Convalescent Plasma Donors
por: Juskewitch, Justin E., et al.
Publicado: (2021)

Commentary on “Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study”
por: Joyner, Michael J., et al.
Publicado: (2022)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

Use of convalescent plasma in COVID-19 patients in China
por: Zhu, M., et al.
Publicado: (2020)

The fossilization of randomized clinical trials
por: Paneth, Nigel S., et al.
Publicado: (2022)

Convalescent plasma in the management of COVID-19 pneumonia
por: Elbadawi, Ayman, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19 convalescent plasma therapy and immunodeficiency
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence
por: Klassen, Stephen A., et al.
Publicado: (2021)

The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis
por: Klassen, Stephen A., et al.
Publicado: (2021)

In Reply — Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma
por: Klompas, Allan M., et al.
Publicado: (2021)

Rethinking the role of COVID-19 convalescent plasma in the critically ill
por: Casadevall, Arturo, et al.
Publicado: (2023)

COVID-19 Convalescent Plasma and Concomitant Therapies in PassITON
por: Casadevall, Arturo, et al.
Publicado: (2022)

Impact of convalescent and nonimmune plasma on mortality of patients with COVID-19: a potential role for antithrombin
por: Gazzaruso, Carmine, et al.
Publicado: (2021)

Convalescent plasma (CP) therapy in patients with COVID-19
por: Cakir, Banu
Publicado: (2021)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
por: Focosi, Daniele, et al.
Publicado: (2023)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
por: Ripoll, Juan G., et al.
Publicado: (2021)

COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
por: Sullivan, David, et al.
Publicado: (2023)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

Limitations of Safety Update on Convalescent Plasma Transfusion in COVID-19 Patients
por: Farag, Youssef M.K.
Publicado: (2020)

Convalescent plasma to treat COVID-19: Its challenges in Iraq's situation
por: Hashim, H.T.
Publicado: (2020)

Challenges in the production of COVID-19 convalescent plasma- analysis of donor recruitment
por: Sekiya, Eliseo Joji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i1vau76v75rkg7fdts8t8ljkp4